首页> 美国卫生研究院文献>Contemporary Oncology >Can we find a good biochemical marker of early cardiotoxicity in children treated with haematopoietic stem cell transplantation?
【2h】

Can we find a good biochemical marker of early cardiotoxicity in children treated with haematopoietic stem cell transplantation?

机译:我们能否为造血干细胞移植治疗的儿童找到早期心脏毒性的良好生化指标?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cardiotoxicity is one of the complications following haematopoietic stem cell transplantation (HSCT), but its diagnosis may be hampered due to the presence of different post-transplant comorbidities. The aim of the study was to assess the incidence of cardiac complications and the significance of biochemical markers (NT-proBNP, ANP, ET-1, and TnI) and ECHO systolic and diastolic parameters analysis in children treated with HSCT. Thirty consecutive children (median age 9.6 years) were included in the study. The control group consisted of 14 healthy children (median age of 10.9 years). None of the transplanted children developed clinical cardiotoxicity. Median ET-1 and NT-proBNP plasma levels were elevated when compared to controls in at least 3 out of 4 analysed time points, median ANP levels differed only in one time point, and no difference was found between median TnI values in all analysed time points. Echocardiographic systolic parameters were within the normal range, while median E/A ratio assessed before HSCT, on day +30, and +100 post-transplant was statistically lower in HSCT patients (respectively, 1.34, 1.37, and 1.42 vs. 1.73). It confirms the need for careful follow up in patients who have received chemotherapy and have been treated with HSCT.
机译:心脏毒性是造血干细胞移植(HSCT)后的并发症之一,但由于存在不同的移植后合并症,其诊断可能受到阻碍。该研究的目的是评估接受HSCT治疗的儿童的心脏并发症的发生率以及生化标志物(NT-proBNP,ANP,ET-1和TnI)的重要性以及ECHO收缩压和舒张压参数分析。该研究包括连续的30名儿童(中位年龄为9.6岁)。对照组包括14名健康儿童(中位年龄为10.9岁)。移植的儿童均未出现临床心脏毒性。与对照组相比,在至少4个分析时间点中的3个时间点,中位ET-1和NT-proBNP血浆水平升高,中位ANP水平仅在一个时间点有所不同,并且在所有分析时间中均未发现TnI中值之间存在差异点。超声心动图的收缩参数在正常范围内,而HSCT患者在移植后第30天和移植后+100天评估的中位E / A比值在统计学上较低(分别为1.34、1.37和1.42比1.73)。它确认了接受化疗并已接受HSCT治疗的患者需要仔细随访。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号